Testosterone Therapy: Evidence-Based Criteria for Clinical Use

The Testosterone Trend: Separating Clinical Indication From Marketing Noise

Testosterone replacement therapy (TRT) has exploded into the mainstream consciousness—billboards, podcasts, direct-to-consumer clinics. Yet the clinical reality is far more nuanced than the marketing narrative suggests. As a physician, I'm concerned about two equal and opposite problems: men with genuine hypogonadism who remain untreated due to stigma, and men with normal testosterone pursuing replacement for performance enhancement.

Let's establish the evidence-based framework for who actually needs testosterone therapy.

Understanding the Diagnostic Threshold

Testosterone doesn't exist as a binary state. It operates on a spectrum, and clinical laboratories define "normal" broadly: typically 300–1000 ng/dL for adult males, depending on the assay. But normal reference range ≠ optimal individual threshold.

The diagnosis of hypogonadism requires:

Persistent low serum testosterone (<300 ng/dL on two separate morning draws, ideally 8–10 AM)
Clinical symptoms consistent with testosterone deficiency: fatigue, reduced libido, erectile dysfunction, mood disturbance, reduced muscle mass, elevated body fat
Exclusion of secondary causes: medication-induced hypogonadism, obesity, sleep apnea, metabolic syndrome, hyperprolactinemia, pituitary/hypothalamic disease

This is critical: testosterone therapy for asymptomatic men with low-normal levels is off-label and unsupported by major guidelines (American Urological Association, Endocrine Society).

The Endocrine Cascade: Why Baseline Testing Matters

Before initiating TRT, you need a complete hormonal panel—not just total testosterone.

Essential labs:

Total testosterone (LC-MS/MS preferred; immunoassay is unreliable below 400 ng/dL)
Free testosterone (calculated or dialysis method; sex hormone–binding globulin–dependent)
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — differentiate primary (testicular) vs. secondary (pituitary/hypothalamic) hypogonadism
Prolactin — elevated levels suppress gonadotropins
Thyroid panel (TSH, free T3, free T4) — hypothyroidism mimics hypogonadism; affects TRT response
Estradiol — baseline critical; TRT increases aromatization to estradiol
DHEA-S — indicates adrenal reserve
Fasting glucose, HbA1c — metabolic baseline
Lipid panel — TRT affects HDL/LDL ratios
Hematocrit/hemoglobin — TRT increases RBC production (polycythemia risk)
Liver function tests — if using oral testosterone (17α-alkylated compounds)
PSA (prostate-specific antigen) — controversial, but baseline critical for risk stratification

Mechanism of Testosterone Action and Systemic Effects

Testosterone operates through the androgen receptor (AR) in target tissues: muscle, bone, adipose tissue, brain, cardiovascular system, prostate.

Key mechanisms affected by TRT:

Anabolic effects:

Increased protein synthesis → lean mass accrual
Improved insulin sensitivity (paradoxically, if baseline insulin resistance present)
Enhanced erythropoiesis (RBC production)

Neurological effects:

Mood stabilization (dopamine/serotonin modulation)
Improved cognitive processing speed and spatial reasoning
Libido restoration

Metabolic effects:

Decreased visceral adiposity
Altered lipid metabolism (often unfavorable: ↓HDL, ↑triglycerides, ↑LDL in some patients)

Cardiovascular risk: This is where the evidence is genuinely mixed. The 2010 TOM trial was halted due to excess cardiovascular events in the TRT arm, but subsequent meta-analyses show heterogeneous results. Current consensus: TRT is safe in physiologic doses for men with documented hypogonadism, but carries risk in men with prior MI, uncontrolled hypertension, or severe sleep apnea.

Synergistic Supplementation for TRT Efficacy

If TRT is indicated, certain supplements optimize endocrine function and mitigate side effects:

Zinc (30–50 mg elemental, citrate or glycinate): Co-factor for 17β-HSD and 5α-reductase; supports LH secretion. Essential baseline; many TRT candidates are zinc-depleted.

Magnesium glycinate (400–500 mg): Improves insulin sensitivity, reduces aromatization stress, supports sleep (critical for hormonal recovery).

Vitamin D3/K2 (4000–5000 IU D3 + 180 mcg K2 MK-7): Enhances androgen receptor expression; synergizes with TRT for bone density.

NAC (n-acetylcysteine, 1200–1800 mg): Reduces oxidative stress from increased metabolic rate; supports liver function during TRT.

Omega-3 (EPA/DHA) (2–3g combined): Protects against TRT-induced lipid dysregulation; anti-inflammatory.

Ashwagandha (600–1200 mg KSM-66): Cortisol modulation; prevents TRT-induced adrenal suppression.

Monitoring During TRT: The Protocol

Month 1–3: Repeat testosterone, estradiol, hematocrit, liver function, lipids. Most side effects emerge here.

Month 6: Full hormonal panel (testosterone, estradiol, LH, FSH, prolactin), lipids, liver function, PSA, hematocrit.

Annually thereafter: Same panel plus fasting glucose/HbA1c, bone density screening (DEXA) every 2 years if age >50 or risk factors present.

Dose adjustment: Aim for mid-range testosterone (500–700 ng/dL) with symptoms improvement. More is not better; higher doses increase cardiovascular and prostate risk without additional benefit.

Who Should Not Use Testosterone

Men with untreated sleep apnea (↑hematocrit risk)
Men with uncontrolled hypertension
Men with prior myocardial infarction (<3 months)
Men with prostate cancer or PSA >4 ng/mL with elevated risk
Men seeking performance enhancement without clinical hypogonadism

Bottom Line

Testosterone therapy is evidence-based for men with symptomatic, documented hypogonadism. It's not a cosmetic intervention or anti-aging panacea. Proper diagnosis requires serum testosterone (<300 ng/dL) plus symptoms plus gonadotropin assessment to differentiate primary from secondary disease. Baseline labs—including glucose, lipids, hematocrit, PSA, and estradiol—are non-negotiable. Monitoring is essential. Used correctly, TRT restores function; used incorrectly, it creates iatrogenic problems.

The trend is real. The evidence is real. But so are the risks of casual prescribing.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.